Centenial Surgical Suture Flags Suspected Trades in 2026

Company seeks scrutiny of price movements

Centenial Surgical Suture Ltd has asked BSE Limited's Investigation or Surveillance Department and the Securities and Exchange Board of India to examine what it describes as unusual trading and abnormal price movements in its shares. The company said the movements were not supported by any material corporate announcement or business development from its side. It has denied the involvement of its promoters, directors, key managerial personnel and their immediate relatives in the trades it has flagged. The complaint adds to an earlier BSE surveillance query dated March 13, 2026 regarding significant movement in the stock price. The exchange sought clarification so that investors would have relevant information about the company and the market could be appropriately informed.

A one-share trade was highlighted

In its October communication, the company cited a transaction on October 21 in which one equity share was traded at Rs 71.25. It said the trade formed part of a pattern that warranted an urgent regulatory review. The company characterised the activity as potentially manipulative and requested an investigation into possible misuse or unethical trading. It also said no material announcement had been made that could explain the observed price changes. The company has sought the protection of shareholder interests and its corporate reputation through the requested review.

Earlier complaints covered February trading

Centenial Surgical Suture had also responded to the BSE's March surveillance inquiry with details of trades between February 6 and February 13, 2026. According to the company, several transactions during that period involved quantities of one to five shares. It alleged that the pattern could have been designed to influence the last traded price of the scrip. The company described the activity as involving possible coordinated buying and selling, though it did not identify the alleged participants in the information provided. Its submission requested a comprehensive investigation into possible violations of SEBI's Prohibition of Fraudulent and Unfair Trade Practices regulations.

Company cites repeated small-lot patterns

The company's representations listed several features it considered suspicious. These included very small transaction sizes, repeated appearances by certain investors, and buyers located across different parts of India. It also alleged synchronised trading and the possible use of upper and lower circuit limits to influence price movements. Centenial Surgical Suture said these traits did not appear consistent with normal commercial trading in the stock. The claims are allegations made by the company, and the supplied information does not state any regulatory finding against a person or entity.

August data was included in allegations

The company also referred to isolated one-share transactions on August 18, August 21 and August 26, 2026. It stated that the share price reached Rs 90.00 on August 18, Rs 98.69 on August 21 and Rs 97.49 on August 26 in transactions it considered unusual. The August 21 and August 26 references each cited a price increase of Rs 4.69, or about 4.99% and 4.64%, respectively. Centenial Surgical Suture said it had made no material corporate announcements to encourage either a significant increase or decrease in the share price. It alleged that the patterns could indicate a price-rigging scheme and requested that the authorities identify those responsible.

Share price remained under pressure

The stock was last reported at Rs 67.95 on October 23, 2026, down Rs 3.30 or 4.63% from its previous close of Rs 71.25. The company’s shares were reported to be trading below their 5-day, 20-day, 50-day, 100-day and 200-day moving averages. The supplied market data also described bearish MACD readings on weekly and monthly charts, while Bollinger Band signals ranged from mildly bearish to bearish. The stock missed one trading day in the preceding 20 sessions, an indication of limited trading activity in the available data. These technical indicators reflect the stock's reported price trend and do not establish the cause of individual trades.

Broader market conditions were weak

The reported weakness came amid a softer broader market environment. The Sensex was stated to be down 0.62% and trading below its 50-day moving average, with that average below the 200-day moving average. Centenial Surgical Suture was said to have marginally outperformed its sector by 0.31% on the day it hit the cited low, although its overall trend continued to lag the sector and benchmark indices. The available information also referred to a prolonged period of weak profitability and investor scepticism about the company's financial health and market positioning. It noted that the stock traded at a discount to peers' historical valuations despite its weak financial track record.

Key reported trading and market data

What the regulatory request means

A request for investigation is not a determination that manipulation occurred. BSE and SEBI may assess trading records, counterparties, order patterns and disclosures before reaching any conclusion. The company has stated that it supplied extensive trading data in support of its complaint. Its repeated communication places the matter within the exchange-surveillance framework, which is intended to monitor significant price and volume movements. Investors will need to rely on any subsequent exchange or regulatory communication for confirmed findings or action.

Focus remains on official updates

Centenial Surgical Suture's complaint centres on its claim that small and unusual transactions affected price discovery without any related corporate trigger. At the same time, the available market data shows the share price had remained under technical pressure by late October. The company has asked authorities to investigate the activity and has denied insider involvement in the alleged conduct. No conclusion from BSE or SEBI is included in the information available. The next material development would be a response, finding or further disclosure from the exchange, regulator or company.